Fluid Challenge in Intensive Care: a Worldwide Global Inception Cohort Study: The FENICE II Study
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Critical Illness
- 发起方
- Humanitas Clinical and Research Center
- 入组人数
- 4734
- 试验地点
- 2
- 主要终点
- Composite of various aspects of fluid therapy
- 状态
- 已完成
- 最后更新
- 2个月前
概览
简要总结
Fluids are considered the primary treatment for critically ill patients admitted to the intensive care unit (ICU), aiming to replace losses and or to enhance venous return, stroke volume, and consequently, cardiac output and tissue oxygen delivery. The modalities, volumes, and targets employed to titrate fluid therapy vary significantly in current clinical practice, as shown by the original FENICE study 10 years ago. FENICE studied how fluid challenges are given at the bedside. Very little is known about how this practice has changed since, how fluid administration (maintenance) is performed in general, and how the modality may impact outcomes. FENICE II is designed to explore these issues.
Objectives:
To provide a comprehensive global description of fluid administration modalities during the initial days of ICU admission and to explore any association between fluid administration characteristics and clinical outcomes.
To describe the fluid challenge administration modality and appraise the use of variables and functional hemodynamic tests to guide bolus infusion.
详细描述
Primary aim: The primary aim is to describe the modality of fluid administration during the first 5 days of ICU stay considering 1) the overall fluid balance; 2) the characteristics of the fluids given; 3) the modality of fluid administration. Secondary aims: * To explore any association between fluid administration characteristics and clinical outcomes (see further) * To evaluate factors potentially associated with the respective proportion of the different modalities of fluid administration * To characterize FC administration modality in a large cohort of ICU patients. Statistical Analysis: Data will be described as median and interquartile range (IQR) or number and percentage. Categorical variables were compared using Fisher's exact test and continuous variables using the nonparametric Wilcoxon test, Mann-Whitney test, or Kruskal-Wallis test. Volume of fluid and fluid balance (primary outcome) will be reported as median \[IQR\] from day 1 to day 5. This volume, fluid balance and respective volume of bolus and continuous fluid administration will be reported as distinct alluvial plots reporting median of fluid at day 1 to 5 per quartile along with outcome. In way to assess relationship between volume of fluid received, characteristics and outcome (secondary outcome), longitudinal cluster modelling will be used to identify clusters of patients with similar patterns of fluid administration profile. Longitudinal k-mean will be used to assess change in fluid received each day from day 1 to day 3. In way to avoid misinterpretation of findings due to time dependent competing events such death or ICU discharge, this analysis will be performed on patients alive and still in the ICU at day 3. A sensitivity analysis will be performed during first 5 days on the subgroup of patients alive and not discharged during first 5 ICU-days. In way to assess impact of fluid administration modality/strategy on outcome (secondary endpoint), factors associated with in-hospital mortality, including identified cluster of fluid administration, will be assessed using mixed logistic regression where in-hospital mortality will be event of interest. Center effect will be included as a random effect against the intercept. For secondary outcomes, and in particular for day-30 mortality, number of days alive without vasopressors, mechanical ventilation or renal replacement therapy, will be assessed using survival analysis. All tests will be two-sided, and P-value less than 0.05 will be considered statistically significant.
研究者
入排标准
入选标准
- •All consecutive adult (≥18 years old) patients admitted to ICU and expected to stay at least 48h.
排除标准
- •Planned admission after surgery for overnight ICU stay.
- •Refusal of consent
- •Moribund patients (i.e. expected survival \< 24h)
结局指标
主要结局
Composite of various aspects of fluid therapy
时间窗: FIve days from ICU admission
Modality of fluid administration during ICU stay considering 1) the overall fluid balance; 2) the characteristics of the fluids given; 3) the modality of fluid administration
次要结局
- ICU mortality(Up to 30 days from ICU admission)
- In-hospital Mortality(Up to 30 days from ICU admission)
- Alive without any organ support(between inclusion and 30 days later)
- Organ Dysfunction - Lung(between inclusion and 30 days later)
- Organ Dysfunction - Heart(between inclusion and 30 days later)
- Organ Dysfunction - Renal(between inclusion and 30 days later)
- Organ Dysfunction(between inclusion and 5 days later)
- Organ Dysfunction - Renal(between inclusion and 5 days later)